Disc Medicine Inc (IRON) FinancialsIRONDisc Medicine Inc

Evaluating the bottom line, Disc Medicine, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -39.08%, provide a clear picture of how effectively IRON converts its operational activities into shareholder value.

In the context of the broader market, IRON competes directly with industry leaders such as CLDX and MBX. With a market capitalization of $3.03B, it holds a significant position in the sector. When comparing efficiency, IRON's gross margin of N/A stands against CLDX's 100.00% and MBX's N/A. Such benchmarking helps identify whether Disc Medicine, Inc. is trading at a premium or discount relative to its financial performance.

Disc Medicine has shown a significant increase in cash reserves, ending Q2 with approximately $718 million, which supports its operations into 2029. However, it has consistently reported negative net income, with losses increasing each quarter, culminating in -$63.5 million in Q1 2026.